We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medical Product Earnings Early Next Week: CAH, ZBH & More
Read MoreHide Full Article
The third-quarter earnings season is seeing possibly the best growth pace since the first quarter of 2015. As of Oct 26, 198 S&P 500 members, accounting for 48.9% of the index’s total market capitalization, reported results, according to the latest Earnings Outlook.
While total earnings for these index members were up 3.2% from the year-ago quarter, revenues were up 1.9% year over year. The beat ratio was 73.7% for earnings and 61.1% for revenues. The Q3 earnings season has seen more positive surprises and fewer negative revisions to the current-period (2016 Q4) estimates.
Notably, the third quarter is on track to be the first quarter of positive earnings growth after five consecutive quarters of earnings decline for the S&P 500 index. The picture is expected to steadily improve hereafter.
Let’s take a look at the major Medical Product stocks slated to release their quarterly reports on Monday, Oct 31:
Cardinal Health, Inc. (CAH - Free Report) : This healthcare services provider is scheduled to report first-quarter fiscal 2017 earnings results, before the opening bell. Generic pricing pressure remains a matter of concern for Cardinal Health. Consequently, management expects generic sales to remain sluggish in the near term. On a brighter note, synergies from the acquisitions of Metro Medical, The Harvard Drug Group and Cordis will remain the key catalysts for this corporation’s growth.
Currently, Cardinal Health holds a Zacks Rank #4 (Sell) and has an Earnings ESP of -1.65%. That is because the Most Accurate estimate is pegged at $1.19, while the Zacks Consensus Estimate is pegged higher at $1.21. (Read More: Cardinal Health Q1 Earnings: Disappointment in Store?)
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) : This stalwart from our Medical Product subsector had reported a positive earnings surprise of 3.06% last quarter. The company has an Earnings ESP of 0.00% and a Zacks Rank #4.
Post dismal dental sales, primarily due to supply disruption linked with a voluntary field action in response to a packaging issue, we are concerned about the looming headwinds that mar Zimmer Biomet’s performance. Also, we are apprehensive about rising operating expenses affecting the third quarter due to the ongoing acquisitions and planned strategic initiatives. (Read More: Zimmer Biomet Q3 Earnings: What's in the Cards?)
Luminex Corporation : Luminex develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical and life sciences industries worldwide. The company will report third-quarter 2016 results after market close. We believe the company is poised to beat the Zacks Consensus Estimate given its Zacks Rank #3 (Hold) and an Earnings ESP of +33.33%. Please check our Earnings ESP Filter that enables you to find stocks that are expected to come out with earnings surprises.
Orthofix International N.V. (OFIX - Free Report) : Orthofix is a Curacao-based medical device provider of reconstructive and regenerative orthopedic and spine solutions across the globe. For the third quarter, the company has an Earnings ESP of 0.00% which complicates surprise prediction even though it carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand. Click for his selected trades right now >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Medical Product Earnings Early Next Week: CAH, ZBH & More
The third-quarter earnings season is seeing possibly the best growth pace since the first quarter of 2015. As of Oct 26, 198 S&P 500 members, accounting for 48.9% of the index’s total market capitalization, reported results, according to the latest Earnings Outlook.
While total earnings for these index members were up 3.2% from the year-ago quarter, revenues were up 1.9% year over year. The beat ratio was 73.7% for earnings and 61.1% for revenues. The Q3 earnings season has seen more positive surprises and fewer negative revisions to the current-period (2016 Q4) estimates.
Notably, the third quarter is on track to be the first quarter of positive earnings growth after five consecutive quarters of earnings decline for the S&P 500 index. The picture is expected to steadily improve hereafter.
Let’s take a look at the major Medical Product stocks slated to release their quarterly reports on Monday, Oct 31:
Cardinal Health, Inc. (CAH - Free Report) : This healthcare services provider is scheduled to report first-quarter fiscal 2017 earnings results, before the opening bell. Generic pricing pressure remains a matter of concern for Cardinal Health. Consequently, management expects generic sales to remain sluggish in the near term. On a brighter note, synergies from the acquisitions of Metro Medical, The Harvard Drug Group and Cordis will remain the key catalysts for this corporation’s growth.
Currently, Cardinal Health holds a Zacks Rank #4 (Sell) and has an Earnings ESP of -1.65%. That is because the Most Accurate estimate is pegged at $1.19, while the Zacks Consensus Estimate is pegged higher at $1.21. (Read More: Cardinal Health Q1 Earnings: Disappointment in Store?)
CARDINAL HEALTH Price and EPS Surprise
CARDINAL HEALTH Price and EPS Surprise | CARDINAL HEALTH Quote
Zimmer Biomet Holdings, Inc. (ZBH - Free Report) : This stalwart from our Medical Product subsector had reported a positive earnings surprise of 3.06% last quarter. The company has an Earnings ESP of 0.00% and a Zacks Rank #4.
Post dismal dental sales, primarily due to supply disruption linked with a voluntary field action in response to a packaging issue, we are concerned about the looming headwinds that mar Zimmer Biomet’s performance. Also, we are apprehensive about rising operating expenses affecting the third quarter due to the ongoing acquisitions and planned strategic initiatives. (Read More: Zimmer Biomet Q3 Earnings: What's in the Cards?)
ZIMMER BIOMET Price and EPS Surprise
ZIMMER BIOMET Price and EPS Surprise | ZIMMER BIOMET Quote
Luminex Corporation : Luminex develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical and life sciences industries worldwide. The company will report third-quarter 2016 results after market close. We believe the company is poised to beat the Zacks Consensus Estimate given its Zacks Rank #3 (Hold) and an Earnings ESP of +33.33%. Please check our Earnings ESP Filter that enables you to find stocks that are expected to come out with earnings surprises.
LUMINEX CORP Price and EPS Surprise
LUMINEX CORP Price and EPS Surprise | LUMINEX CORP Quote
Orthofix International N.V. (OFIX - Free Report) : Orthofix is a Curacao-based medical device provider of reconstructive and regenerative orthopedic and spine solutions across the globe. For the third quarter, the company has an Earnings ESP of 0.00% which complicates surprise prediction even though it carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ORTHOFIX INTL Price and EPS Surprise
ORTHOFIX INTL Price and EPS Surprise | ORTHOFIX INTL Quote
Confidential: Zacks' Best Investment Ideas
Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand. Click for his selected trades right now >>